ReviewJournal of biological engineering2026
Advanced biomimetic nanomedicines for cell-based therapeutics: prospects and challenges.
Review in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Advanced biomimetic nanomedicines offer cell-based therapeutics to mimic biological behaviors for improved targeting, immune evasion, and integration with living cells. This review critically examines recent innovations in biomimetic nanocarriers especially leveraging from cell membranes, membrane proteins, or native cellular structures to support cell therapies. These systems aid in prolonging circulation, reducing immunogenicity, and directing therapeutic cells to disease sites. Membrane-coated nanoparticles, metal-phenolic network-based nanovaccines, and stem-cell-membrane-coated carriers have therapeutic potential but challenges of manufacturing, scalability, quality control, in vivo stability, and regulatory barriers are present. To overcome these challenges, substituted hybrid membrane formulations, bio-responsive release mechanisms, and modular design are adopted. This review aims to guide future research toward clinical viable biomimetic nanomedicines for cell-based therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.